VR Adviser’s Mineralys Therapeutics MLYS Stock Holding History

VR Adviser’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-555,554	Closed	-$7.17M	–	42
2024 Q1	$7.17M	Buy	+555,554	New	+$6.86M	0.34%	35

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

VR Adviser's MLYS Position: Q2 2024 in Review

VR Adviser sold out of Mineralys Therapeutics (MLYS) in Q2 2024, closing a stake of 555,554 shares — an estimated $7.17M sold.

VR Adviser first reported a position in MLYS in Q1 2024 and held it in 1 quarter. The position peaked at $7.17M in Q1 2024. 94 funds tracked by Wall St. Rank hold MLYS as of Q2 2024.

VR Adviser reported no remaining Mineralys Therapeutics position as of Q2 2024 after selling out during the quarter.
VR Adviser sold 555,554 Mineralys Therapeutics shares in Q2 2024, an estimated $7.17M.
VR Adviser first reported a position in Mineralys Therapeutics in Q1 2024 and held it in 1 quarter.
VR Adviser's Mineralys Therapeutics position peaked at $7.17M in Q1 2024.
94 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2024.

Based on VR Adviser's 13F filing for Q2 2024, filed 14 Aug 2024.